Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines
Tat’Yana A. Kenigsberg, Eric Weintraub, Laura P. Hurley(Hospital Authority), Matthew F. Daley(Kaiser Permanente), Lisa A. Jackson(Kaiser Permanente Washington Health Research Institute), Kayla E. Hanson(Marshfield Clinic), Nicola P. Klein, Amelia Jazwa(Centers for Disease Control and Prevention), Stephanie A. Irving(Kaiser Permanente Center for Health Research), Stanley Xu(Kaiser Permanente), Kristin Goddard(Kaiser Permanente Oakland Medical Center), Bradley Crane, Ned Lewis(Kaiser Permanente), Tia L. Kauffman, Robyn Kaiser(HealthPartners), Allison L. Naleway(Centers for Disease Control and Prevention)
Cited by 9
Related Papers
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
|New England Journal of Medicine|2021|937
Effects of the COVID-19 Pandemic on Routine Pediatric Vaccine Ordering and Administration — United States, 2020
|MMWR Morbidity and Mortality Weekly Report|2020|720
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
|New England Journal of Medicine|2021|661
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices — United States, June 2021
|MMWR Morbidity and Mortality Weekly Report|2021|602